Brodalumab and ixekizumab, to treat psoriasis
| Author : Pierre Allain
||Date : 2012-5-2
Interleukin-17 is a cytokine secreted by CD4+ T cells, it activates the corresponding receptor, IL-17R. Interleukin-17 is present in high concentration in psoriasis plaques. Two antibodies neutralize the effects of interleukin-17, one blocking the receptor of interleukin-17, brodalumab, and the other neutralizing the interleukin-17 itself, ixekizumab.
A paper published in the NEJM of March 29th, 2012 shows that brodalumab administered subcutaneously, in general one injection per week, compared to placebo, has considerably reduced the importance of psoriasis lesions with relatively few adverse effects.
Another paper published in the NEJM of March 29th, 2012 shows that ixekizumab in subcutaneous injections, an injection every two weeks, compared to placebo, considerably reduced the clinical symptoms of psoriasis with relatively few adverse effects.
There is no comparison brodalumab versus ixekizumab.
It should be recalled that one of the physiological functions of interleukin-17 is to reinforce defence against infections; long-term inhibition of interleukin-17 could increase the infectious risk?